Bull and Bear

Figures converted from EUR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — the franchise is genuine, management is exceptionally aligned, and the compounding identity has held for three straight years; but you are paying 2.91× tangible book at the late-cycle moment for a deal that consumes the M&A optionality the multiple paid for, and the first clean Q1 miss since 2023 has already printed. Bull's track record (14 deals, all clearing the 20% RoTCE hurdle) is more durable than Bear's "peak-cycle" rhetoric admits, but Bull's price target leans on a 3.25× P/TBV that has no margin of safety against the very risk-cost trajectory Bull does not directly answer. The decisive tension is mechanical: any quarter of RoTCE below 22% — Bull's own disconfirming threshold — resets the multiple toward Bear's 1.80× math. The right action is to wait for one clean post-PTSB-closing print where badwill reconciles to identifiable marks and risk costs settle below 35 bps before sizing up.

Bull Case

Price target: $216 over 12–18 months, derived as 3.25× P/TBV applied to FY2027e tangible book of ~$66.71/share (cross-checks at ~13× FY2027e EPS of ~$16.62). The slight premium to today's 2.91× reflects PTSB lifting the through-cycle RoTCE glide path, not multiple expansion. Primary catalyst: February 2027 FY2026 results when management confirms PTSB closing in H1 2027 with day-one accretion intact and reaffirms FY2027 net profit >$1.29bn ex-PTSB. Disconfirming signal: Group RoTCE under 22% in any quarter through FY2027, or PTSB closing slips past Q4 2027.

Bear Case

Downside target: $117 over 12–18 months (≈31% below $170.50 spot), derived as P/TBV compression from 2.99× to ~1.80× applied to FY2026e TBVPS of ~$64.95; cross-checks at ~9.0× a normalised $12.87 EPS. Primary trigger: Q3 or Q4 2026 trading updates showing risk costs holding above 40 bps with NIM compressing through 3.0%, and the PTSB closing disclosure showing larger-than-flagged day-one balance-sheet marks. Cover signal: A clean PTSB closing print where badwill reconciles to identifiable mark-downs with no residual cookie-jar reserve, Q4 2026 RoTCE above 24% with risk costs back below 30 bps, and reaffirmed FY2028 standalone net profit >$1.40bn with PTSB tracking >20% day-one accretion.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. Bull carries more weight on the structural questions — the compounding identity, the 14-deal M&A track record, and the $613M of personally-paid-for management equity are facts about a franchise, not forecasts. But Bear wins the most important tension: the multiple-versus-RoTCE arithmetic. At 2.91× tangible book versus a 7-year average of 1.45×, the stock is underwriting that group RoTCE never prints below 22% during the largest integration in BAWAG's history while unsecured consumer credit is entering its first cycle test, while ECB cuts compress NIM, while a Supervisory Board with five first-year directors oversees the closing — and the first clean miss since 2023 has already arrived in Q1 2026. Bear could still be wrong: AIB at 25% RoTCE on a 44% CIR is a real read-through, the $293M PTSB profit add is a credible 2028 deliverable, and SRT funding is a rational tool when used for capital headroom rather than rescue. The verdict moves to Lean Long if the H1 2027 PTSB closing print shows badwill reconciling cleanly to identifiable marks plus restructuring, FY2026 risk costs settle below 35 bps, and group RoTCE holds above 24% through closing. The verdict moves to Avoid if any quarter through FY2027 prints RoTCE under 22% or PTSB closing slips past Q4 2027.